SynergyMed

SynergyMed is a private medical technology company developing a noninvasive cancer treatment platform intended to replace or complement surgical tumor resection in both human and veterinary medicine. Its system uses external electromagnetic energy together with injected FDA-approved nanoparticles to achieve localized thermal ablation while aiming to spare surrounding healthy tissue. The company has reported animal data in mice and dogs and has advanced into a veterinary clinical study with The Ohio State University, positioning the veterinary market as an early commercialization pathway. SynergyMed is focused primarily on superficial solid tumors, including breast, head and neck, skin, and lung cancers, and describes its technology as a platform that could also support palliative care applications. The business appears to be an early-stage private oncology device company rather than a therapeutics developer.